Wegovy stories

Jul 17, 2026

India approves Wegovy for fatty liver disease treatment

India's drug regulator approved Novo Nordisk's obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease, expanding the drug's approved uses beyond weight loss.

Jul 17, 2026·1 source

May 7, 2026

Novo Nordisk Reports Positive Earnings on Oral Wegovy Development Progress

Novo Nordisk's stock price and earnings received a boost following less-negative news about the development of an oral version of its blockbuster weight loss drug Wegovy, marking progress in the company's efforts to create a pill formulation.

May 7, 2026·1 source

Top claims

▪The approved dosage of Wegovy for MASH treatment is a 2.4 mg semaglutide injection.
▪MASH is a serious form of fatty liver disease caused by a buildup of fat in the liver that can lead to inflammation and liver damage.
▪India's drug regulator, the Central Drugs Standard Control Organisation, approved Novo Nordisk's drug Wegovy for treating metabolic dysfunction-associated steatohepatitis (MASH).

Topics

Metabolic health Novo Nordisk Obesity treatment GLP-1 medications Corporate earnings Big Tech stock performance

Weight management

Related entities

India Liver disease

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

Aug 7, 2026·2 sources